Lit Matters 2: Peripheral nerve blocks for primary headache disorders

Primary headache treatment in the ED still hinges on ruling out secondary causes, but peripheral nerve blocks appear to offer a safe adjunct for rapid pain reduction. For migraine, cluster, and tension-type headache, the clearest signal is early benefit from sphenopalatine ganglion and occipital approaches.

Peripheral Nerve Blocks for Headache

• Early pain reduction signal: Peripheral nerve blocks lowered headache pain versus placebo at 15 and 30 minutes, suggesting a real early effect even if the average benefit fell short of a preset clinically significant change.
• Sphenopalatine ganglion block: The SPG block stands out for ease of administration and favorable safety, making it a practical adjunct to standard migraine therapy; the bedside setup is worth hearing in the episode.
• Occipital and trigger options: Greater occipital nerve blocks and trigger point injections were also included, reinforcing that this is a broader primary headache strategy rather than a single-technique result.
• Primary headache population: The evidence applies to benign, nontraumatic primary headaches such as migraine, cluster, and tension-type headache, not secondary headache from hemorrhage, infection, or other dangerous causes.
• Safety profile reassurance: Across 11 randomized studies with 860 patients, no serious adverse events were reported, supporting nerve blocks as a low-risk adjunct when usual headache treatments are already underway.
• Adjunct not replacement therapy: The key takeaway is to consider nerve blocks alongside standard headache medications, because direct comparisons against usual care were too limited to establish them as standalone first-line treatment.